Efficacy and Tolerability of Intravenous Zometa® (Zoledronic Acid) 4 mg in Primary Breast Cancer Patients With Disseminated Tumor Cells in Bone Marrow. A Prospective, Randomized, Parallel Group, Open-label, Clinical Pilot Study.
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Reduction of detected tumor cells in bone marrow
12 months
No
Novartis Pharmaceuticals
Study Director
Novartis Pharmeceuticals
Germany: Federal Institute for Drugs and Medical Devices
CZOL446GDE05
NCT00172068
January 2002
Name | Location |
---|